University of Rhode Island

DigitalCommons@URI
Open Access Dissertations
2016

Epigenetic Pathways Involved in Response to Lead (PB) Exposure
in the Aging Brain: Relevance to Alzheimer's Disease
Aseel Eid
University of Rhode Island, aseel.eid@gmail.com

Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss

Recommended Citation
Eid, Aseel, "Epigenetic Pathways Involved in Response to Lead (PB) Exposure in the Aging Brain:
Relevance to Alzheimer's Disease" (2016). Open Access Dissertations. Paper 511.
https://digitalcommons.uri.edu/oa_diss/511

This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for
inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more
information, please contact digitalcommons@etal.uri.edu.

EPIGENETIC PATHWAYS INVOLVED IN RESPONSE
TO LEAD (PB) EXPOSURE IN THE AGING BRAIN:
RELEVANCE TO ALZHEIMER’S DISEASE
BY
ASEEL EID

A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
DOCTOR OF PHILOSOPHY
IN
INTERDISCIPLINARY NEUROSCIENCES

UNIVERSITY OF RHODE ISLAND
2016

ABSTRACT
Alzheimer’s Disease (AD) has a complicated pathology with many potential
etiologies. In patients, a diagnosis of AD is confirmed at the time of autopsy by
the presence of two major pathological hallmarks: the amyloid beta plaque (Aβ
plaque) and the neurofibrillary tangle (NFTs). The late-onset (LOAD) form of
this disease has no clear genetic etiology, with the exception of an increased
risk of carrying the APOE4 allele. Therefore, research has focused on
identifying environmental risk factors in its etiology. Our lab has a legacy of
studying environmental exposure to lead (Pb) during early development. We
have shown in previous publications that exposure to Pb during early life
results in the upregulation in a number of key genes in the amyloid and tau
pathways directly related to the development of the characteristic hallmarks of
AD.
In this dissertation, Manuscript I was a review of the literature related to Pb
exposure in both children and adults, and the role Pb has in
neurodegenerative diseases, either by workplace exposures or by
developmental basis of diseases. The focus of the review was also to present
evidence from our work and others to suggest the mechanism by which these
changes occur, via potential epigenetic pathways.
Manuscript II was aimed to investigate the involvement of epigenetic pathways
in the developmental model of Pb exposure, in which (wild-type mice were
exposed to 0.2% Pb from PND 1 and 20 Western blot and RT-PCR analysis
were performed for a number of key epigenetic marks and regulators across

the lifespan in the cortex of mice developmentally exposed to Pb. Alterations
in a number of key mediators involved in DNA methylation were identified
across the lifespan, as well as specific alterations in histone marks involved in
both repression (H3K27me3) and activation (H3K9Ac, H3K4me2) pathways.
Activating histone proteins were globally downregulated in the cortex whereas
the repression mark was increased at the end of life.
Manuscript III, utilized the innovative technique of ChIP-seq to identify H3K9Ac
binding peaks in the mouse genome across the lifespan of developmentally
Pb exposed mice. Unique peaks were present in the Pb exposed animals, with
an emphasis on peaks in the promoter were reported. Of the genes affected, it
was found many were associated with AD pathology by utilizing the Kegg’s
pathway thingy, specifically it was shown that genes have acetylation islands
in or near the promoter that were differentially acetylated in Pb exposed mice
later in life. Therefore, by these findings show that epigenetic regulation,
specifically by H3K9Ac, could be a potential mechanism by which AD-related
genes become upregulated late in life.
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PREFACE
This dissertation was prepared following the manuscript format. It has been
divided into three manuscripts that relate to the effects of lead exposure on
epigenetic marks and regulators. The first manuscript is a review article on the
consequences of lead exposure in human populations, its relevance to
neurodegenerative disease and the possibility of epigenetic involvement in this
process, it has been accepted and published in the journal of Neurotoxicology.
The second manuscript examines the alterations that occur to DNA
methylation regulators and histone marks following developmental exposure to
mice across the lifespan, this manuscript has been accepted and published in
Alzheimer’s and Dementia: Diagnosis and Disease Monitoring Journal. The
final manuscript identifies the effects of lead on a specific histone mark,
H3K9Ac at various timepoints in both control and lead exposed mice across
the lifespan, this manuscript has been prepared following the Epigenomics
journal guidelines.
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ABSTRACT: Lead exposure has primarily been a concern during
development in young children and little attention has been paid to exposure
outcomes as these children age, or even to exposures in adulthood.
Childhood exposures have long term consequences, and adults who have
been exposed to lead as children show a host of cognitive deficits. Lead has
also been shown to induce latent changes in the aging brain, and has been
implicated in the pathogenesis of neurodegenerative diseases, particularly
Alzheimer’s Disease, and Parkinson’s. Recent research has shown that lead
has the ability to alter DNA methylation, histone modifications, and miRNA
expression in experimental models, and in humans. These findings implicate
epigenetics in lead induced toxicity, and long term changes in individuals.
Epigenetic modification could potentially provide us a mechanism by which the
environment, and toxic exposures contribute to the increased susceptibility of
adult neurodegenerative disease.
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1.0 Introduction
As we age our bodies grow increasingly susceptible to environmental
injury and insults, the brain in particular is at great risk [1]. Interestingly, there
aren’t many toxicants that are discussed in the context of age related changes
and abnormalities. A classic neurotoxin, that has been studied for it’s role in
childhood and developmental toxicity is the environmental agent lead (Pb).
Historically, the toxic effects of lead have been researched and documented
extensively as related to children and adolescents, however, the impact of
past exposure to lead on the aging brain was not a major concern. There have
been devastating cases of lead encephalopathy involving both adults and
children, which is defined as a medical emergency, and observed when
individuals have blood lead levels (BLLs) over 70 µg/dL [2]. Infants who have
suffered acute exposure experience sever brain damage, and impaired
neurological outcomes at doses even lower than what is considered lead
encephalopathy (56 µg/dL) [3].
A dangerous property of lead is it’s ability to interact and bind to calcium
[4]. Over 95% of lead stores have been found to be deposited into bone, and it
is considered a primary source of exposure. Measurements of both blood and
bone lead levels provide researchers with evidence on how recent and past
lead exposure may have occurred. Lead has been shown to be mobilized from
the bone during periods of the human lifespan in which bone resorption/growth
are occurring, for example during osteoporosis and pregnancy [5], giving lead
the ability to induce toxic effects over prolonged periods of time, without recent
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exposure. Lead has also been shown to compete with Zinc, in a number of
physiological interactions. It has a similar affinity for motifs and receptors that
are typically occupied by zinc, and ultimately is able to modify transcription.
The effects of lead exposure on transcription, and it’s dynamics with zinc have
been extensively reviewed [6] .
In this review, we will discuss some of the classical outcomes as a
result of lead exposure, but will focus on the role of lead in neurodegenerative
and adult disease. We will introduce the role lead may have in regulating gene
expression by way of epigenetics, and provide compelling evidence for lead as
an epigenetic modifier.
1.1 Adult consequences of Childhood Exposure to Lead
Childhood exposure to environmental lead has been heavily implicated
in cognitive dysfunction during early years. The toxicant has been identified as
a clear disruptor of neurodevelopment in early life, shown to impair academic
performance in school age children, and to negatively impact intelligence
scores [7-13]. Furthermore, children who have unfortunately been exposed to
lead during development have shown cognitive dysfunction that continues into
adulthood. Early studies examined children who suffered from lead
encephalopathy in the first four years of life, were found to have decreased
scores on a battery of neuropsychological tests [14]. Similar findings were
reported in a group of young adults (aged 19-29), who resided nearby a lead
smelter facility during childhood [15]. More recently, a study conducted in
Boston MA examined young adults (mean age 29) and their cognitive function,
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by IQ tests. Individuals were known to have low-level (<10µg/dL)
environmental lead exposure during childhood, and had measurements of
blood lead taken at 6, 12, 18, 24 and 57 months, and again at 10 years of age
[16]. The study reported lower IQ test scores in individuals with higher levels of
exposure during childhood [16].
Longitudinal studies have been carried out to characterize the changes
in brain development that are associated with this early exposure, namely in
terms of brain volume reduction in specific regions. The Cinncinatti Lead
Study (CSL) recruited a birth cohort from Cincinnati between 1979-1984,
infants were excluded if they had low birth weight, or medical issues [17]. The
CSL reported childhood BLLs were associated with regions of brain volume
reduction in adult gray matter. Specifically this loss occurred in the prefrontal
cortex, in regions associated with executive function control, behavioral
modulation and fine motor control [18]. Furthermore, a subset of adults were
recruited to high resolution volumetric magnetic imaging, and these changes
were related to mean blood levels in the first six years of life. Significant
inverse associates between age, gray matter volume and BLLs were
observed, with the strongest reductions in adult gray matter associated with
BLLs measurements at 5 and 6 years of age [19]. Further analysis of this
cohort revealed significantly decreased levels of N-acetyl asparatate
metabolite in gray matter as measured by proton magnetic resonance
spectroscopy [20], these findings were replicated in a similar cohort [21].
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These observations implicate lead in long lasting brain abnormalities that
impact cognitive function negatively.
1.2 Exposures in adult populations
Evidence that exposure to lead is associated with cognitive decline is
present from several longitudinal and cross-sectional epidemiological studies
in the elderly. The onset of cognitive decline is an important intermediary for
the development of neurodegenerative diseases, specifically Alzheimer’s
disease. The Baltimore Memory Study (BMS) was conducted to investigate
determinants of cognitive decline while taking into account variables such as
socioeconomic status, and environmental exposures [22, 23]. The cohort
included individuals aged between 50-70 years, who lived in neighborhoods
near Baltimore MD, and measured both blood and tibia lead levels [22, 23].
Results from the BMS indicated mean tibia levels were inversely correlated
with cognitive function in all six domains tested, such as executive functioning,
processing speed, and verbal memory and learning [22, 24]. Similar findings
were reported by the Normative Aging Study (NAS) which began in 1963 and
was conducted at the Veterans Affairs outpatient clinic in Boston, MA [25].
NAS enrolled 2,000 male veterans with the goal of investigating processes
behind normal aging. They examined lead bone levels and results of the minimental state examination within this cohort, and reported higher bone levels
are associated with worsened cognition [26, 27]. These findings were
expanded in subsequent years, and the cohort was examined using a battery
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of cognitive tests, such as the Wechler Adult Intelligence Scale- Revised
results indicated a further decline in cognitive scores across all domains [28].
While most of the studies performed have focused on examining
cognitive function in males, there are a small number that have contributed to
our understanding of the effects of lead primarily on women. The Nurse’s
Health Study established in 1976 began to collect health information from
registered nurses in the United States, the study has continued to monitor
health outcome changes every two years until the present day, and has a
participation of >90% of individuals since its establishment [29]. Weuve et al,
reported on a subset of the Nurse’s study, and examined blood, tibia, and
patella levels of lead in relation to current cognitive function in community
dwelling women. The study identified the three biomarkers of lead exposure
were associated with worsened cognitive function in women, however only
tibia levels were significantly higher [30]. These studies were replicated by
others, where tibia levels were significantly associated with cognitive decline
[31].
1.3 Occupational exposures
Due to our increased knowledge and awareness of the dangers of lead
toxicity, exposures have been relatively controlled for most community
dwelling individuals, while those exposed to lead in the workplace remain at
risk. Both cross-sectional and longitudinal studies have been conducted in in
workers exposed to lead, with studies occurring both in the United States and
abroad. The Lead Occupational Study originally began in 1982, and examined
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288 male workers with exposure to lead for a minimum of one year, while
working at a lead battery plant in Pennsylvania. Cognitive functions were
analyzed using the Pittsburg Occupational Exposures Tests (POET) [32].
POET results of this initial analysis found only significant associations between
bone and BLLs and psychomotor speed [33, 34]. Members of this cohort were
analyzed again to examine longitudinal changes in cognitive function. Khalil et
al., reported that individuals who were reexamined had lower cognitive
performance compared to control, as well as lower cognitive performance
longitudinally. Unlike the initial study, the cognitive disruptions were observed
between peak tibia lead levels, spatial ability, learning and memory and overall
cognitive scores as determined by the POET battery test. Furthermore, when
these results were examined by age it was determined that older individuals
(>55 years) had more severe cognitive declines and dysfunctions than their
younger counterparts [35].
These findings were also observed in the Organolead study, which
began in 1994 to examine the effects of tetraethyllead manufacturing on
cognitive functioning, based on earlier efforts from researchers at Johns
Hopkins [36]. The cohorts last known lead exposure was 16 years prior,
results indicated mean tibia lead levels were inversely correlated with
neurobehavioral tests scores in the domains of manual dexterity, executive
functioning, intelligence and memory [37]. Individuals were examined again
two years later, with further associations of cognitive decline in relation to tibia
lead levels in all areas [38]. Studies abroad have also focused on studying the
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effects of lead exposure in the workplace. The Korea Lead Study began in
1997 and examined both current and former inorganic lead workers in the
republic of Korea. The study employed 803 lead workers, and cognitive tests
were employed similar to those in the organolead study, which were a
modified version of the world health organization neurobehavioral core test
battery [39]. Of these tests, higher lead blood levels, and not tibia lead levels
were associated with worse performance on eight of the tests, which were
associated with measuring executive functioning, and manual dexterity.
Indicating BLLs as a better predictor of worse neurobehavioral scores [39].
The cohort was examined again following two years, measures at this time
point showed BLLs consistent with earlier reports, with declines in both
cognitive test scores related to manual dexterity and executive ability.
Furthermore, individuals had worsened cognitive scores, consistent with
cognitive decline associated with the cumulative lead exposure [40].
Functional associations between the cognitive deficits and anatomical
brain changes have been undertaken by Stewart, Schwartz and colleagues on
former organolead workers living in the eastern United States. Study
participants were past organolead workers with 18 years mean time from their
last exposure, and with a mean age of 56 years at time of enrollment. Bone
lead concentrations were measured for individuals, and MRI data collected
[41]. Cumulative lead dose was found to be associated with increased risk,
and increased severity in white matter lesions. Investigators also observed
total brain volume reduction, as well as reduction in specific brain regions such
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as the cingulate gyrus, and insula. Effects observed by lead exposure were
equivalent to reductions seen due to 5 years of aging [41]. Indicating that lead
has a significant role in altering the architecture of the brain involved in
cognition, and executive function and could potentially lead individuals to be
more susceptible to the aging process.
2.0 Neurodegenerative Disease
It has been well established that as humans age, they become more
vulnerable to a host of diseases, including cardiovascular disease, cancer and
neurodegenerative disease [42, 43]. The nature for this is elusive to
researchers, however there are some theories in the literature in regards to
what may occur during the course of our lifetime, to make us more susceptible
to these devastating diseases. Early life exposures and disease have been
discussed since the 1980s, with the “Barker Hypothesis” that essentially states
that adult diseases have a connection to the fetal environment, such as
maternal stress and or diet. This early work primarily focused on adverse fetal
events such as low birth weight, and their connections to the development of
adult cardiovascular disease as the individual ages [44, 45]. Similarly, the
developmental origins of health and disease (DOHaD) also describe the
postnatal day period as a major window of vulnerability to adult latent disease,
and just as important as the fetal environment [46].
It has been theorized that due to the accumulation of environmental
stressors over the lifetime, that individuals become vulnerable to a host of
neurological diseases. For example, the latent early life associated regulation
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model (LEARn) describes a hypothesis in which environmental agents play a
role in disease pathology by perturbing gene regulation in late life [47]. These
environmental stressors are identified as “hits” that make individuals more
susceptible to the development of neurological diseases as they age, typically
by inducing epigenetic changes in the genome [47]. In a recent review,
authors have described a number of exposure models that have contributed to
the development of neurodegenerative disease, including in utero conditions,
exposure to metals or pesticides, and dietary and lifestyle habits [48]. A
number of studies have identified lead as a potential contributor, or risk factor
in the development of neurodegenerative diseases. This section will focus on
those insults that are associated with both development and occupational
exposure to lead, pulling from both epidemiological and experimental data to
demonstrate the potential role of lead in neurodegenerative diseases.
2.1 Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder
that results in brain atrophy of cortical and hippocampal areas and is
accompanied with the development of dementia. There are two pathological
hallmarks of the disease, the amyloid beta (Aβ) plaque, and neurofibrillary
tangle (NFTs), both of which are formed from the abnormal processing and
accumulation of the amyloid precursor protein (APP) and microtubule
associated protein tau (MAPT) respectively [49] .
While there is limited information regarding large-scale occupational
and developmental exposure to lead in humans and the development of AD in
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late life, there are some unique studies that have still managed to identify
connections between exposure, and the disease pathology. The earliest
example was obtained from the examination of a patient post mortem who
survived a case of severe lead encephalopathy early in life, (2 years of age).
The individual exhibited signs of mental deterioration, cortical, temporal and
hippocampal atrophy. But most significantly, there was a presence of both
neurofibrillary tangles, and senile plaques [50]. Studies of organolead workers
16 years following the post recent exposure identified strong declines in
cognitive function, that were more associated with individuals with the
apolipoprotein E4 (ApoE4) allele variant. APOE4 has been implicated as a
potential risk factor in late-onset AD (LOAD) [51]. Most recently, lead
exposure in utero has been implicated in AD [52]. Measurements in these
individuals in young adulthood (28-30 years of age) showed elevated
expression of 196 genes, specifically ADAM9, RTN9, LRPAP1 that are
involved in the clearance and production of Aβ [52].
Previous studies in animals have shown developmental exposure to
lead in early life results is an observed overexpression of AD-related proteins
in late life. Initial observations were conducted in rodent models, with lead
exposure during postnatal day (PND) 1-20. Analysis of gene and protein
expression in late life identified an upregulation of APP, and the cleavage
enzyme Beta-secretase 1 (BACE1), consequently higher levels of both
cleavage products Aβ40 and Aβ42, which compromise Aβ plaques were also
significantly higher [53, 54]. Further analysis of this cohort revealed that lead
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also altered the expression of tauogenic proteins. Total tau, phosphorylated
tau, and enzymes involved in tau phosphorylation were increased at the end
of life in animals developmentally exposed; this was accompanied by cognitive
deficits [55]. Results were further verified and reported in a primate model,
with exposure to lead acetate (1.5 mg/kg/day) occurred from PND 1-400 [5658]. Unlike rodents, primates are able to develop Aβ plaques and
neurofibrillary tangles, and these animals showed increased presence of both
pathological hallmarks in late life [56, 57]. Findings in primates implicate this
developmental lead in the production of important pathological hallmarks of
the disease, and strengthen the potential role for lead in the developmental
basis of AD.
2.2 Parkinson’s Disease
Parkinson’s disease (PD) is a movement disorder, which is
characterized by bradykinesia, rigidity, tremor and postural instability.
Neuronal cell loss occurs in the substantia nigra, with primarily dopaminergic
cells loss [59]. The first evidence that exposure to lead may contribute to the
development of PD, was found in 1997 [60]. This pioneering study examined a
group of patients with idiopathic PD, and their age matched controls at Henry
Ford Medical Center in Detroit. Individuals, who had an occupational exposure
of over 20 years of either lead-copper or lead-iron, were found to have greater
risk for developing PD. Other studies measured levels of lead deposited in
trabecular and cortical bone, and revealed that higher lifetime exposure to
lead is associated with an increased risk of PD by more than two fold in
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individuals [61]. These findings were replicated in a larger cohort of
individuals, and tibia bone lead levels were significantly associated with an
increased risk for developing PD [62].
2.3 Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) or more commonly known as Lou
Gherigs disease is a neurodegenerative disease that involves the
degeneration of lower and upper motor neurons [63]. Initial observations in
occupationally exposed individuals identified lead as a risk factor for the
development of ALS [64]. Further observations in US veterans examined
mobilization of lead from bone, and the potential association with an increased
risk of ALS. The study concluded that elevated blood lead is associated with
higher chances of the development of ALS regardless of both bone turnover,
or δ-aminolevulinic acid dehydratase (ALAD) genotype. Ultimately, incidence
of ALS was higher in those individuals with past lead exposure, and an
increase in BLLs is associated with a 2-fold increase risk for ALS [65]. These
findings were supported by a recent meta analysis consisting of nine casecontrolled epidemiological studies of occupational lead exposure and ALS risk
[66]. More recently, it has been investigated if individuals with single
nucleotide polymorphisms such as the HFE-H63D, are at a greater risk for
ALS when coupled with lead exposure. Investigators have associated patella
lead levels with a higher incidence of ALS, and with the co-representation of
this polymorphism, that is associated with iron overload and increased
oxidative stress [67].
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3.0 The Role of Epigenetics
The aberrant nature of sporadic neurodegenerative diseases, and the
little to no genetic connection to their etiology points to an environmental
component playing a role in their pathogenesis. The environment is believed
to either be a driving factor, or to increase an individual’s susceptibility to
neurodegeneration with age [68]. The major mechanism by which
environmental toxicants could be playing a role in neurodegeneration is via
epigenetic control of gene expression. Epigenetics is the study of alterations,
or changes in gene expression without altering the underlying DNA sequence.
Environmental agents have been heavily studied in their ability to induce
epigenetic changes relative to diseases such as cancer, but recently these
observations have been made for neurological diseases.
DNA methylation is the most common type of epigenetic regulation
studied. It is the process by which DNA methyltransferases (DNMTs) add a
methyl group to the 5’ position of cytosine in CpG rich regions, by way of the
methyl donor S-adenosyl methionine (SAM) [69, 70]. Methylation patterns are
maintained by DNA methyltransferases such as DNMT1, DNMT3a, and
DNMT3b, and the functional consequence of the recruitment of methyl groups
and repressive binding proteins at the promoter region of genes is association
with repression of gene expression [71, 72]. The nucleosome is the major
component of chromatin consisting of DNA base pairs wrapped around an
octamer of histone proteins, composed of two copies of Histone 2A (H2A),
H2B, H3 and H4 with modifications to the N-terminus tail typically occurring in
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the form of methylation, acetylation and phosphorylation [73, 74]. Typically,
acetylation at lysines on H3 and H4 are associated with regions of chromatin
that are open to transcription, and typically indicate gene activation. Whereas
histone methylation marks such as H3K27me3, and H3K9me3 are involved
with gene repression. Both histone modifications and DNA methylation have
been shown to work in tandem to regulate gene expression by altering the
conformation and accessibility of chromatin regions [75, 76]. Epigenetic
regulation is also maintained by noncoding RNA’s, that bind to specific mRNA
transcripts, and inhibit their transcription [77, 78]. The field of miRNA research
is still new, and our understanding is primitive with comparison to DNA
methylation, and histone modifications.
Epigenetic changes have been identified in a wide host of disease
states. Primarily, this work was initially performed in oncology, with distinct
DNA methylation patterns associated with cancer subtypes [79]. This work has
also lead to the inclusion of DNA methylation patterns as potential biomarkers
for a number of cancers [80, 81]. Epigenetics patterns, and epigenetic
regulation of disease has also been observed in neurological disease states,
including neurodegenerative diseases. In blood and brain measurements of
PD patients, differential methylation patterns were observed in a number of
genes relative to age-matched controls [82]. Observations in cellular models of
ALS exhibited an upregulation of DNMTs and 5-methylcystosine (5MC). These
findings were also observed in human ALS motor neurons, implicating DNMT
proteins as potential drivers for neurodegeneration [83]. Hypomethylation was
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reported at the APP promoter of an AD patient and consequently an
upregulation of APP [84]. Further genome wide methylation studies in
postmortem patients diagnosed with late-onset Alzheimer’s disease revealed
948 CpG sites representing 918 genes that may be associated with this form
of the disease. Further analysis will need to be performed to identify if the
methylation status of candidate genes actually participate in the disease
pathology [85].
Proteins involved in regulating histone and DNA dynamics have also
been altered in Alzheimer’s disease patients. A number of studies have
identified increases in histone deacetylase proteins, such as HDAC6 and
HDAC2 while DNMT1 levels were significantly reduced [86-88]. miRNA have
also been found to be involved in neurodegenerative diseases. MiR107 is
known to regulate BACE1 in human frontal cortex samples from AD patients.
During the early pathogenesis of AD miR107 is upregulated and inversely
related to BACE1, however as the disease progresses miR107 decreases,
BACE1 levels are upregulated, and are involved in increased Abeta
metabolism [89]. In PD patients, miR-34b and miR-34c were downregulated
relative to age-matched control patients [90].
3.1 Lead as an Epigenetic Modifier
We have seen the emergence of a strong role for lead as a potential
modifier of gene expression via epigenetic regulation, summarized in Figure 1.
Some of the earliest information has come from the Zawia group, at the
University of Rhode Island in their developmental studies of lead exposure in
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an animal model of AD (discussed above). An early study examined both DNA
methylation regulators and histone modifications in macaca fasicularis
exposed to 1.5mg/kg/day of lead acetate from PND1-PND400. At 23 years of
age exposed primates were found to have decreased levels of DNMT1,
DNMT3a, and MeCP2 proteins involved in regulation DNA methylation, as well
as significantly lower levels of acetylated histones [58]. In the same cohort of
animals, DNMT1 activity was also lowered following lead exposure [56].
Similar findings were also observed in differentiated SHSY5Y cells. Human
neuroblastoma cells were treated with increasing concentrations of lead
acetate, and DNMT proteins and MeCP2 were significantly decreased [91].
Lifespan studies in mice have revealed genome wide dysregulation of
DNA methylation in latent life following exposure. Methylation and gene
expression profiles were overlaid and analyzed in animals at PND20 and
PND700 following exposure, the results indicated a global repression profile of
genes in late life, with a small subset of genes being overexpressed [92, 93].
Data from the Zawia lab have shown significant decreases of DNMT1, and
MECP2 across the lifespan of wild type mice following developmental
exposure to lead [94].We have also identified upregulation of H3K9Ac, and
downregulation of H3K27me3, indicating that lead has the ability to reprogram
the epigenome across the lifespan [94].Further studies in this same cohort
identified a dysregulation in miRNA across the lifespan a well, with significant
changes in miRNA involved in AD pathology [95].
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Studies from other groups have also identified lead as a disruptor of
epigenetic control of gene expression. In mice, perinatal exposure to lead
resulted in a downregulation of DNMT1 and MECP2 at PND 55 in the
hippocampus [96]. In rats chronically exposed to lead, the expression of 7
miRNA were altered. These miRNA have been previously shown to regulate
genes involved in neurodegeneration, and processes involved in
synaptogenesis and neuronal injury [97]. Acetylated histone 3 levels were also
significantly increased with lead concentration (4mg/L, and 25mg/L), and
associated with an increased hyperactivity in rats [98]. Lead exposure in
human embryonic stem cells has been shown to alter DNA methylation status
of genes involved in neural signaling [99]. Further analysis by this group has
revealed that early exposure can disrupt 5-hydroxymethylation (5hmC) at CpG
clusters in both human embryonic stem cells and umbilical cord blood. Studies
of lead exposure in occupational cohorts have also identified DNA promoter
methylation changes, individuals showed hypomethylation for LINE-1 [100],
and hypermethylation of ALAD genes [101]. Umbilical cord blood was
obtained from the Early Life Exposure in Mexico to Environmental Toxicants
(ELEMENT) cohort and has potentially revealed both 5mC and 5hmC genomic
loci that could be markers for prenatal lead exposure [102]. Lead induced
changes in methylation have also been recently reported as transgenerational,
with incredible data indicating that a mother’s BLLs and methylation status,
can directly impact that of her children [103]. This is the first work to indicate
transmittable epigenetic regulation in response to an environmental toxicant.
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4.0 Conclusion
The recognition of lead as a toxicant that endangers childhood welfare
enabled many changes across the United States, and the world. Lead levels
began to historically drop as the health dangers began to be recognized,
leading to the current safety level of 5µg/dL [104] . These changes resulted in
the eradication of lead based paint, as well as the removal of lead from
gasoline [105, 106]. Despite these efforts lead exposure remains a prominent
threat to children as well as adults across the world. In the United States, the
current “safe” levels of exposure to lead are 5µg/dL for children. However,
there have been studies to identify cognitive impairments at blood levels close
to 5ug/dl, and even below, implying that there may not be any safe level of
exposure [107-109].
Lead exposure still remains as a large risk for specific populations,
specifically children. Unlike adults, children retain 32% of lead that is ingested,
thereby making any exposure to lead that they encounter significantly
dangerous [110]. Individuals living in urban areas, such as New Orleans are at
great risk for exposure due to increased levels in the environment [111-113].
Despite regulations leading to the closing of lead smelters, areas and
populations that have resided nearby continuously experience higher lead
blood levels than are considered safe, and lead remains integrated in the
environment. In 2012 a study examining BLLs in inner-city neighborhoods in
Indianapolis IN reported 8% of children had BLLs higher than 10µg/dL [114].
With the passing of the new BLLs safety recommendation by the CDC, these
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neighborhoods reported 27% of children with BLLs higher than the 5µg/dL
[115]. In Flint MI a recent study has reported that 4.9% of children under the
age of five had levels higher than the recommended 5µg/dL [116, 117].
Residential areas in developing countries are also still highly exposed to lead,
with individuals utilizing equipment that is either made from lead, or living in
environments where the drinking water is heavily contaminated [118-123].
We have presented information and arguments to explain the
challenges that environmental lead exposure poses to the aging brain. We
argue that lead toxicity occurs across the lifespan, and that developmental
exposures have long term consequences. Typically adults have been lower of
concern when it comes to classical lead toxicity due to the development of the
blood brain barrier. Despite this, we have compiled evidence to suggest that
even exposures that occur during adulthood are associated with devastating
outcome. Therefore, lead remains a real and prominent threat as an agent that
is involved in the pathology of adult disease. Not only does it contribute to
cognitive deficits in both children and adults, it could potentially be involved in
the etiology of several neurological diseases. The ability of lead to work by
epigenetic processes and pathways presents as a major challenge for how
scientists consider it’s toxicological effects. As we continue to learn and
uncover the role of epigenetic modifications in disease, we must be wary of
agents that have been shown to exhibit epigenetic actions, and what the
functional consequences could be.
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Figure 1: Epigenetic alterations following exposure to lead 1) Exposure
has consistently shown to decrease MeCP2, and DNMT1 and DNMT3a levels
in the literature. A decrease in these enzymes that govern DNA methylation is
consistent with hypomethylation of genes. 2) It has also been shown to both
induce hypermethylation when analyzed by DNA methylation arrays, and also
promoter specific hypo/hypermethylation by groups depending on the target
gene being studied. Observations are consistent with upregulation of the
repressive H3K27me3 (3), and downregulation of active H3K4me2 (4),
whereas depending on the source and timing of exposure, lead induced
upregulation/downregulation has been observed for H3K9Ac (5). Lead
regulation of these mechanisms affects the transcript of the target gene.
Whereas lead induced changes in miRNA expression (6) would either
increase the availability of miRNA to bind to mRNA of the target gene resulting
in a change in protein levels.
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Abstract:
Background: Early life lead (Pb) exposure results in a latent increase in
Alzheimer’s disease (AD) related proteins, and cognitive deficits late in life in
both rodents and primates. This study was conducted to investigate if these
late life changes were accompanied by epigenetic alterations
Methods: Western blot analysis and RT-PCR were used to measure DNA
methylation regulators (DNMT1, DNMT3a, MeCP2, MAT2A) and histone
proteins (H3K9Ac, H3K4me2, H3K27me3).
Results: Cerebral levels of DNMT1 and MeCP2 were significantly reduced in
mice exposed to Pb early in life, whereas the expression of DNMT3a was not
altered. Levels of MAT2a were increased in the Pb-exposed mice across the
lifespan. H3K9Ac and H3K4me2, involved in gene activation, were decreased,
while the repressive mark H3K27me3 was elevated.
Conclusion: Epigenetic modifiers are affected by the developmental exposure
to Pb, and may play a role in mediating the latent increases in AD related
proteins in the brain.
Keywords: Aging; Alzheimer’s disease; Epigenetics; Lead (Pb); Lifespan
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I. Introduction
According to the 2015 Alzheimer’s Report, there are currently 5.3
million Americans living with AD [1]. The vast majority of these individuals
(>95%) are 65 years of age or older, with a disease subtype known as lateonset AD (LOAD). The remaining 5% of cases make up early-onset AD
(EOAD), and of these (<1%) are linked to mutations in one of three genes,
Amyloid Precursor Protein (APP), Presenilin-1 (PSEN1), and Presenilin-2
(PSEN2) [2]. LOAD is challenging to researchers, the presentation of the
disease is sporadic as patients exhibit non-Mendelian characteristics. To date,
there is no clear genetic etiology for LOAD, other than a risk factor of carrying
specific susceptibility alleles [3, 4]. The single and only proven risk factor for
the development of this sporadic form of AD is aging. These observations
suggest the involvement of environmental and/or epigenetic factors across the
lifespan in the initiation and development of the disease [5].
Early studies have provided evidence that many chronic adult diseases
and disorders, such as cardiovascular disease, diabetes and obesity, are
linked to environmental exposures that occurred during development [6, 7].
Importantly, there is also a growing body of literature to support the contention
that exposures to environmental toxins in early life contribute to the
development of at least some of the neurodegenerative disorders [8].
There are few epidemiological studies examining the link between
environmental exposures and development of LOAD. These studies have
assessed relationships between past exposures to pesticides, metals, dietary
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changes and other environmental influences, however the results have been
limited. We have taken a specific interest in the environmental agent and
heavy metal lead (Pb). Since Pb has been implicated as a neurotoxin for
generations, and is known to have devastating consequences for the nervous
system, specifically in children [9]. The metal is non-degradable, ubiquitously
found in nature, has high bioavailability, can cross the blood brain barrier and
has a long half-life [10]. Epidemiological studies assessing both occupational
exposure and exposures in community dwelling individuals have identified Pb
as a clear disrupter of cognitive performance and function [11, 12]
Our lab was among the first to provide evidence that exposure to an
environmental Pb in early life results in latent overexpression of AD-related
proteins and histopathology in late life [13-16]. Reports by us have also
demonstrated a latent increase in both amyloidogenic and tauogenic proteins,
as well as behavioral deficits in our rodent models [13, 17]. These results have
been replicated, and further investigated in a primate model, where we have
also reported the presence of tangles and plaques in the cerebral cortex [14,
16]. More recently, we have shown that the changes in the expression of
proteins such as APP, amyloid beta (Aβ) and microtubule-associated protein
tau (MAPT) are accompanied by epigenetic changes [14, 18]. Epigenetics
refers to the process that results in modifications in gene activity independent
of the primary DNA sequence [19]. DNA methylation alterations and histone
tail modifications are the most widely studied forms of epigenetic
modifications.
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This study documents the expression of four enzymes important in
regulating DNA methylation and three histone modifications (two activating,
one repressive) across the lifespan of animals that were exposed to Pb during
a brief period of early postnatal life. Our results provide a valuable framework
for understanding a number of epigenetic interactions that likely play a critical
role in the expression of neurotoxic AD-related proteins in later life. This work
is the first to identify epigenetic changes across the lifespan following a
developmental exposure that has been previously shown to have significant
increases in AD related biomarkers.
2. METHODS
2.1 Animal Exposure:
C57BL/6 mice were bred in house in the Animal Care Facility at the
University of Rhode Island, according to previously published protocols [15,
17]. All experiments were performed in accordance with the standard
guidelines and protocol approved by the University of Rhode Island
Institutional Animal Care and Use Committee (IACUC) with supervision of the
university's veterinarian. Males were divided into two groups, and used in this
study. The control group received regular tap water, whereas the second
group (PbE, developmental exposure) was exposed to 0.2% Pb-acetate from
PND 1 to PND 20 through the drinking water of the dam. Animals receiving
Pb-acetate had no observable adverse developmental deficits. Brains were
dissected at the following ages: PND 20, 180, 270, 540 and 700 and stored at
-80°C until use. These animals are from the subset of the same cohort that
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has already been characterized for Alzheimer’s pathology and behavioral
deficits [15, 17].
2.2 Total RNA isolation, synthesis of cDNA, and real time PCR
Total RNA was isolated from the cerebral cortex following the TRIzol
method (Invitrogen, Carlsbad, CA). Samples were checked for integrity and
purity by NanoDrop (Thermo Fischer Scientific, Waltham MA). First strand
complementary DNA (cDNA) was synthesized using the iScript cDNA
Synthesis Kit (Bio-Rad, Hercules, CA). Approximately 1 µg of RNA was diluted
in 19 µl of water, with 4 µl 5x iScript reaction mix, and 1 µl of iScript reverse
transcriptase. Samples were incubated at 42°C for 90 minutes, followed by
85°C for 5 minutes using the MJ Research MiniCycler PTC-150 (Bio-Rad).
Real-time PCR was carried out in 12.5 µl reaction volumes containing 1 µl of
cDNA template, 4.75 µl nuclease free water and 6.25 µl SYBR® Green PCR
Master Mix (Applied Biosystems, Foster City, CA).

Real-time PCR was

performed using the ViiA 7 Real-Time PCR System (Applied Biosystems)
utilizing the following conditions: 50 oC for 2 minutes followed by 95 oC for 10
minutes then 40 cycles of 95 oC for 15 seconds and 60 oC for 1 minute.
Expression data was reported using the 2-ΔΔCT method and GAPDH mRNA as
the endogenous control. The primer pairs used are presented in Table 1.
2.3 Protein Extraction
For DNMT1, DNMT3a, and MECP2 the nuclear fraction was collected
according to the method described by Dignam et al, with minor modifications
[20]. Samples were homogenized in 1 ml phosphate buffer saline (PBS) at pH
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7.4 followed by centrifugation at 2500x g for 10 minutes. The pellets obtained
were resuspended in 5 volumes of buffer A (10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 0.5 mM DTT, 0.5 mM EDTA, and 0.2 mM PMSF) and centrifuged at
600x g for 2 minutes at 4°C. The pellets were resuspended in 3 volumes of
buffer A and centrifuged at 600x g for 2 minutes at 4°C. Following
centrifugation, pellets were then resuspended and homogenized in 5 vol of
buffer C (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM EDTA,
420 mM NaCl, 20% glycerol, 0.2 mM PMSF, 2 µg/ml aprotinin, 0.5 µg/ml
leupeptin). Suspensions were centrifuged at 12,000x g for 10 minutes at 4°C,
supernatants were collected, frozen and stored at -80°C until use. Cytoplasmic
protein samples were isolated using the NE-PER nuclear and cytoplasmic
extraction reagents according to the manufacturer’s instructions (Thermo
Fischer Scientific).
2.4 Histone Extraction
Total histones were extracted using the EpiQuick Total Histone Extraction
Kit (Epigentek, Farmingdale, NY) following the manufactures instructions, with
minor modifications. Cortical tissue was weighed and cut into 1-2 mm pieces
and homogenized at 200 mg/ml with prelysis buffer. The homogenate was
centrifuged at 10,000 rpm for 1 minute at 4oC. The supernatant was discarded,
and the pellet was resuspended in 3x volume of lysis buffer and incubated on
ice for 30 minutes. The sample was centrifuged at 12,000 xg for 5 minutes at
4oC and the supernatant was transferred to a fresh vial. Balance buffer was

41

added to the supernatant (0.3 mL to 1 mL supernatant). The extract was
placed at -80°C for long-term storage.
2.5 Western Blot Analysis
Protein concentration was determined by using the Micro BCA Protein
Assay Kit (Thermo Fischer Scientific). Protein samples were then denatured
and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) at 150 V for 1-2 hours, and then transferred to polyvinyl
diflouride (PVDF) membranes (GE-Healthcare, Piscataway, NJ), blocked for 1
hour with 5% bovine serum albumin (BSA) and then immunoblotted with the
appropriate primary antibody. For MAT2A, 40 µg of cytoplasmic extracts were
separated on 10 % SDS-PAGE gels and incubated overnight with primary
polyclonal antibody at the dilution 1:1000 of ab77471 (Abcam, Cambridge,
UK). Membranes were then stripped and reprobed with 1:2000 dilution of
monoclonal A3854 (Sigma-Aldrich, St. Louis, MO) for β-actin. For DNMTs and
MeCP2 proteins, 100 µg of nuclear extracts were separated on 5% SDSPAGE gels and incubated overnight with primary monoclonal antibodies (Cell
Signaling, Danvers, MA) 1:1000 dilution of D59A4 for DNMT1, D23G1 for
DNMT3a and D4F3 for MeCP2. Membranes were then stripped and reprobed
with

1:2000

dilution

of

G8795

(Sigma-Aldrich,

St.

Louis,

MO)

for

Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). For histone proteins,
the following primary polyclonal antibodies (Epigentek) were employed at a
1:5000 dilution, A-4022 for H3K4me2, A-4022 for H3K9Ac, A-4039 for
H3K27me3, A-4035 for H3K9me3 and A-1112 for total H3. 10µg of histones
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were separated onto 16% gels and incubated overnight with the respective
primary antibody. Membranes were then washed four times with tris buffered
saline with Tween 20 (TBST), and incubated with appropriate infrared-labeled
secondary antibody (Li-Cor, Lincoln, NE) at 1:10000 for 1 hour at room
temperature in the dark. Infrared band signals were detected and quantified
using an Odyssey Infrared Imaging System (Li-Cor). MAT2A protein was
normalized against β-actin, whereas nuclear proteins were normalized against
levels of the housekeeping protein GAPDH. Histone proteins were normalized
against bands for total H3.
2.6 Statistical Analysis and Data Representation:
Western blot analysis was performed using the Odyssey Infrared
Imaging System (Li-Cor, Lincoln, NE). Real-time PCR analysis was completed
using the applied biosystems ViiA7 software. Each data set has either an n=3,
or n=4 (designated in the figure legend), the animals were measured
independently without pooling of brain tissue or samples. Individual data
points are presented on each graph, as well as the mean for each group. The
vertical bars represent 95% confidence intervals and are shown for each data
set. The significance of difference between different treatment groups was
determined by one-way analysis of variance (ANOVA), with the Holmes-Sidak
post hoc test using IBM SPSS statistics 21 software. The significance of
interaction between treatment groups and time was determined by two-way
analysis of variance. The level of significance was set at α=0.05. The change
in protein levels with respect to each time point were analyzed by ANOVA with
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the Dunnetts post hoc test.
3. RESULTS
We have previously measured Pb concentrations in animals exposed under
the same protocol as the one in this manuscript and found the concentration of
Pb in the cerebellum of PND 20 rodents (0.25 +/- 0.07 µg/g) to be
approximately three times the level seen in control animals [21]. Blood levels
have been shown to be 46.43 µg/dl during Pb exposure but are reduced to
basal levels in adults [13]. The current recommended levels by the CDC is that
of 5 µg/dL, even though the blood levels in our exposure scenario are higher
they are still consistent with the levels seen in both children and adults
exposed to environmental Pb [22, 23].
3.1 Effect of Pb exposure on the expression of DNMT1 and 3a protein
There was no significant interaction effect between Pb treatment and time.
The exposed mice had a statistically significant decrease in normalized
DNMT1 levels at all time points across lifespan relative to the control animals.
In both the control group and Pb-exposed animals DNMT1 protein expression
was decreased at all time points relative to PND20. (Figure 1.A). Unlike
DNMT1 protein levels, DNMT3a showed no significant difference between
control and Pb-exposed animals across the lifespan of the mice (Figure 1.B).
3.2 Levels of MeCP2 protein across the lifespan following exposure
MeCP2 protein levels normalized relative to GAPDH are increased at day
270 in both the control and Pb-exposed animals; however these results are
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not significant. Statistically significant decreases between the Pb exposed
group and the control group are observed at day 180, and 540 as seen in
Figure 2.A. The remaining time points exhibited no significant difference
between Pb exposed and controls. The control group exhibited no differences
in proteins levels from PND 20 at any other time point. Whereas in the Pbexposed animals, there was significant differences in protein expression
observed at all timepoints except for PND 270. There was also no significant
interaction effect between Pb treatment and time.
3.3 Protein levels of MAT2A protein across the lifespan and following Pb
exposure
The cytoplasmic protein expression profile of MAT2A across the lifespan of
control groups did not display any significant change (Figure 2). However,
mice exposed to Pb as infants demonstrated a statistically significant increase
in levels of MAT2A at day 270, 540, and 700 relative to control. Similarly there
is no interaction effect between time and treatment.
3.4 Alterations in gene expression of DNA mediators following Pb exposure
Changes in gene expression of Dnmt1, Dnmt3a and Mecp2 were also
examined by Real-Time PCR analysis. We observed no significant difference
between mRNA levels of Dnmt1, across the lifespan between the control and
Pb exposed animals (Figure 3.A). Dnmt3a mRNA levels for the Pb exposed
animals were elevated compared to controls across the lifespan, and
significantly increased at PND 20 (Figure 3.B). In figure 4.C mRNA for MeCP2
is significantly lower at PND 20 and PND 270 for the exposed group, with no
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change at any other time point. There was no significant interaction effect for
any of these mRNA targets.
3.5 Effect of Pb on activating and repressive histone marks across the lifespan
Histone extracts were used to profile histone modification marks across the
lifespan via western blot. The activating marks are shown in Figure 4. H3K9Ac
protein levels were significantly lower in the Pb exposed mice for all time
points except PND 20, as seen in Figure 4.A. In the control animals, there was
significant differences compared to PND 20 at both PND 270 and 540, and in
the Pb-exposed animals significance was observed at all timepoints relative to
day 20. H3K4me2 levels have a similar trend, the Pb exposed mice have
lower protein levels compared to controls across the lifespan, with the only
significant decrease occurring at PND 20 (Figure 5.B). Similarly, there were no
significant changes at any of the time points relative to day 20 in either the
control group, or Pb-exposed group. Representative blots for H3K9Ac and
H3K4me2 are seen in Figure 4.C, with total Histone H3 as a loading control.
Protein levels for H3K27me3 are shown in Figure 5. H3K27me3 is a histone
mark indicative of gene repression. Pb exposed animals showed significantly
higher levels of H3K27me3 across the lifespan except for day 180. In the
control animals, all time points exhibited significant differences relative to
PND20, whereas in the Pb-exposed animals significance was only observed at
PND 270 and PND 540. A representative blot for H3K27me3 is shown in
Figure 5.B.
DISCUSSION
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Epigenetic regulation is a complicated phenomenon with converging
pathways involved in the regulation of gene expression. DNA methylation is
maintained by DNA methyltransferases such as DNMT1, DNMT3a, and
DNMT3b, and involves the recruitment of MeCP2 as well as other proteins[24].
Typically recruitment of methyl groups and methyl binding proteins is indicative
of a decrease in gene expression, and is associated with repressive
complexes [25]. Histone tail acetylation is associated with regions of chromatin
that are open to transcription, and typically indicate gene activation. Whereas
specific histone methylation marks such as H3K27me3, and H3K9me3 are
associated with regions of condensed chromatin, and gene repression.
This in-vivo study uncovered a significant decrease in DNMT1 levels
relative to their age-matched controls across the lifespan of mice
developmentally exposed to Pb , with a significant decrease in MeCP2 levels
at some time points as well. These findings are consistent with our previously
published results indicating that differentiated SHSY5Y cells treated with
increasing concentrations of Pb have a significant decrease in DNA
modification enzymes, and MeCP2 [18]. DNMT1 is an important regulator of
tissue specific DNA methylation patterns; exposure to metals such as Cd
have been shown to alter the activity and protein levels of this enzyme [26].
We have also previously examined the ability of Pb to alter the activity of
DNMT1 in tissue, and have found that exposure to Pb does decrease DNMT1
activity [14]. Studies from other groups have also examined changes in protein
levels of DNMT1, and MECP2 as a result of postnatal and perinatal Pb
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exposure [27]. They reported a downregulation in these DNA methylation
modifiers in the hippocampus at PND 55 following Pb exposure. Our results
are consistent with their findings, indicating that Pb exposure down-regulates
these proteins in the cerebral cortex, and that this repression is never
recovered. The data points collected in our study indicate that even at PND
700 there is downregulation of DNMT1, and MeCP2 is maintained.
The results obtained from studying the gene expression of these DNA
methylation regulators leads us to believe that Pb is most likely decreasing
their protein expression directly, and perhaps not through transcriptional
regulation. There was no significant change in mRNA levels for DNMT1, but
there was a decrease in protein relative to controls across the lifespan. A
possible mechanism for this may be due to increases in protein degradation of
DNMT1 following exposure. Similarly, MeCP2 mRNA was only significantly
lower at the PND 20 and PND 270 time point. The most interesting
observation obtained from the gene expression data is for DNMT3a. DNMT3a
gene expression for the Pb treatment was higher across the lifespan, and
significantly increased at PND 20, whereas the protein levels were not
significantly different in the lead exposed animals relative to control. These
data are explained by a recent finding from our lab showing that following
exposure to Pb, as well as an increase in miR-29b (targeting DNMT3a) at
PND20, suggesting that the miRNA leads to a degradation of DNMT3a mRNA
and subsequently why we don’t observe a change in DNMT3a protein levels
[28]. The same paper reported an is an increase of miR-106 (Targeting APP)
48

at PND 700 [28]. There is also evidence that miRNA expression is effected by
chronic Pb exposure in an adult rat hippocampus [29]. Our observations with
DNMT3a are also consistent with previously published work by our lab
indicating that DNMT3a gene expression is 2 fold decreased at PND 700 for
the Pb treated group as compared to PND 20 in primates [30].
MAT2A catalyzes the formation of S-adenosylmethione (SAM) from
methione and ATP and is an important regulator of the methylation cycle. It
has been well documented that SAM levels have been found to be
significantly decreased in the cerebrospinal fluid of patients with AD [31]. In
our study we have shown that Pb exposed mice have elevated levels of
MAT2A across the lifespan compared to their age matched controls. A recent
study in hepatoma cells has shown that upon hypoxia exposure, DNA
demethylation pathways are activated whereas MAT2A expression is upregulated. [32]. In order to better understand the role of MAT2A and the
changes of gene expression we will have to further investigate it’s role in
regulating the DNA methylation pathway in our model.
Histone modifications refer to additions of chemical groups to N-terminus
tail of histone proteins, most commonly the histone core proteins, H3 and H4.
Histone acetylation levels are governed by histone acetyltransferases (HATs)
and deacetylases (HDACs), whereas histone methylation by histone
methyltransferases (HMTs). It is known that histone modifications and DNA
methylation interact to alter the conformation, and thus the accessibility, of the
promoter and coding regions of the genome [33]. In this study, we have shown
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that early life Pb exposure was found to decrease H3K9Ac, and H3K4me2
proteins levels, both of which are marks for gene activation. We have also
shown that H3K27me3 levels are increased, which also is indicative of gene
repression. These are consistent with our previous findings in our primate
tissue, where we observed that histone repressive marks were upregulated,
and the majority of genes are downregulated following Pb exposure[34].
Although much information can be gained from understanding the
changes in the regulation of DNA methylation enzymes and proteins, we are
limited in that we have not identified specific genes that are directly affected in
the alteration of binding of these modifiers. We are also trying to investigate
the mechanisms by which Pb exposure may contribute to the dysregulation of
these proteins. It appears from these studies and previous studies, that
following Pb exposure there are groups of genes that are upregulated, and
others that are repressed. This upregulation of specific genes may be
facilitated by DNA hypomethylation, whereas the gene repression may be
histone-mediated. The changes that have been previously reported in this
animal model report increases in AD related proteins latent in life, whereas the
dysregulation observed in the epigenetic regulators occurs throughout the
lifespan [15, 35]. Future studies will examine the alterations in DNA
methylation, as well as histone modifications that occur at specific genes and
the consequences that has for the expression of those genes. The implications
of this work and the findings obtained from studying histone modifications and
DNA methylation are vast. Targeting epigenetic marks is becoming recognized
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as a novel therapeutic approach for neurodegenerative disease, including AD
[36]. Treatments that have been explored include histone deacetylase (HDAC)
inhibitors, such as valproic acid, and S-adenosylmethionine supplementation
as a method to target DNA methylation changes [36].
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Figure 1
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Figure 1: DNA methyltransferase (DNMT) protein levels across the
lifespan following developmental exposure to lead (Pb). (A) Quantification
of DNMT1 protein expression levels across the lifespan for control animals
and those developmentally exposed to Pb. (B) Quantification of DNMT3a
protein levels across the lifespan following developmental Pb exposure. (C)
Representative DNMT1 and DNMT3a proteins levels. Nuclear extracts were
used and proteins were measured by western blot analysis as described in the
methods section. Individual data points are represented on the graph, as well
as the means for each time point. N=3 and significance is represented as
*P<0.05, ** P<0.01, *** P<0.001. † is used to denote significance from the
PND20 group for the control animals, while # is used to denote significance
from the PND20 time point for the lead exposure group.
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Figure 2
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Figure 2: Methyl CpG binding protein 2 (MeCP2) and Methionine
adenosyltransferase 2a (MAT2a) levels across the lifespan following
developmental exposure to lead (Pb). (A) Quantification of MeCP2 protein
expression levels across the lifespan for control animals and those
developmentally exposed to Pb. (B) Quantification of MAT2A protein
expression levels across the lifespan for control animals and those
developmentally exposed to Pb. (C and D) Representative MeCP2 and
MAT2A protein levels. Nuclear and cytoplasmic extracts were used and
proteins were measured by western blot analysis as described in the methods
section. Individual data points are represented on the graph, as well as the
means for each time point. N=3 for MeCP2 and N=4 for MAT2A and
significance is represented as *P<0.05, ** P<0.01, *** P<0.001. † is used to
denote significance from the PND20 group for the control animals, while # is
used to denote significance from the PND20 time point for the lead exposure
group
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Figure 3
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Figure 3: mRNA levels of DNA methylation regulators across the lifespan
following developmental exposure to lead (Pb). (A) Quantification of
DNMT1 mRNA across the lifespan for control animals and those
developmentally exposed to Pb. (B) Quantification of DNMT3a mRNA across
the lifespan for control animals and those following infantile exposure. (C)
Quantification of MeCP2 mRNA across the lifespan for control animals and
those developmentally exposed to Pb. Individual data points are represented
on the graph, as well as the means for each time point. N=3 or N=4 and
significance is represented as *P<0.05, ** P<0.01, *** P<0.001. † is used to
denote significance from the PND20 group for the control animals, while # is
used to denote significance from the PND20 time point for the lead lead
exposure group.
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Figure 4

62

Figure 4: Activating histone protein levels across the lifespan following
developmental exposure to lead (Pb). (A) Quantification of H3K9Ac protein
expression levels across the lifespan for control animals and those
developmentally exposed to Pb. (B) Quantification of H3K4me2 protein levels
across the lifespan following developmental Pb exposure. (C) Representative
histone proteins levels. Histone extracts were used and proteins were
measured by western blot analysis as described in the methods section.
Individual data points are represented on the graph, as well as the means for
each time point. Individual data points are represented on the graph, as well
as the means for each time point. N=3 and significance is represented as
*P<0.05, ** P<0.01, *** P<0.001. † is used to denote significance from the
PND20 group for the control animals, while # is used to denote significance
from the PND20 time point for the lead exposure group.
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Figure 5
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Figure 5: Repressive histone mark levels across the lifespan following
developmental exposure to lead (Pb). (A) Quantification of H3K27me3
protein expression levels across the lifespan for control animals and those
developmentally exposed to Pb. (B) Representative H3K27me3 protein levels.
Histone extracts were used and proteins were measured by western blot
analysis as described in the methods section. Individual data points are
represented on the graph, as well as the means for each time point. N=3 and
significance is represented as *P<0.05, ** P<0.01, *** P<0.001. † is used to
denote significance from the PND20 group for the control animals, while # is
used to denote significance from the PND20 time point for the lead
exposure group.
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Abstract
Introduction: Early life exposure to lead (Pb) has been shown to increase
biomarkers involved in Alzheimer’s disease (AD) pathology in wild-type mice in
late life. In this same cohort, we observed significant changes in both activating
and repressing histone proteins.
Methods: Chromatin Immunopercipitation Sequencing (ChIP-seq) technology
was used to map histone acetylation at lysine 9 (H3K9Ac) binding to the mouse
genome. Using bioinformatics methods we were able to align sequence reads to
the genome, and then filter and examine the unique peaks from the Pb exposed
group at each timepoint.
Results: Developmental exposure to lead increases H3K9Ac at a number of
gene promoters in animals previously exposed to Pb across the lifespan. A
number of these genes have been implicated in AD pathology.
Discussion: The increase of H3K9Ac peaks at the promoter of genes at day 700
indicates that there is a high chance that they are upregulated. Specifically the
presence of the activation mark at AD promoter supports our hypothesis for the
role of histone proteins in our model.

Keywords: Alzheimer’s Disease; Epigenetics; Histone Acetylation; Lead (Pb)
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1. Introduction
Environmental exposures have long been postulated to play a pivotal role
in both promoting, as well as preventing disease. Numerous studies identify
positive habits such as a healthy diet rich in polyphenols, regular exercise, caloric
restriction and others as safeguarding against most cancers, metabolic
syndrome, and neurological disease [1, 2]. Conversely, exposures from toxins
and toxicants have been adversely associated with disease states. Among these
are an increased risk of type two diabetes as a result of exposure from food
contaminants such as persistent organic pollutants (POPs)[3]. Recent findings
have also shown significantly increased levels of the organochloride βhexachlorocyclohexane (β-HCH) in patients with Parkinson’s disease relative to
their age-matched controls [4]. Similarly serum levels of DDE the metabolite of
DDT were 3.8 fold higher in patients with Alzheimer’s disease (AD) [5].
The critical window for exposure in adult diseases occurs during early
development, including both perinatal and postnatal exposures. Evidence for an
increased risk of disease states has been referred to as the developmental basis
of disease, and has been tied to many adverse states including metabolic
syndrome and neurological diseases [6-8]. Specifically in AD, where the vast
majorities of cases are late-onset with no clear etiology, the environment is
thought to play a major role [9]. One proposed mechanism by which the
environment may alter the expression of genes and predispose to AD is via
epigenetic pathways [9, 10].
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Epigenetic mechanisms refer to changes in our genome that affect gene
expression without altering the underlying DNA sequence. Of these, the most
commonly studied are DNA methylation and histone modifications. DNA
methylation involves the addition of methyl groups to the cytosine residues of
DNA. Recruitment of methyl groups to CpG islands of genes is usually involved
in silencing of that particular region of the genome [11-13]. In the cell, DNA is
organized around histone proteins, and histone tails can be modified by a
number of posttranslational modifications that will either repress or enhance gene
expression. Both DNA methylation and histone modifications work by recruiting
other chromatin binding proteins to alter the structure of chromatin and recruit
either activating or repressive elements [14, 15]. Specifically histone acetylation
is involved in active gene expression, and is associated with loose binding of the
histone proteins to the DNA, which in turn allows inclusion of transcriptional
machinery [14, 15].
Our lab has extensively shown that early life exposure to lead (Pb) can
have significant impacts on behavior in mice, and that this exposure is also
associated with an increase in proteins involved in Alzheimer’s pathology.
Specifically, we have reported statistically significant protein and mRNA levels of
the amyloid precursor protein (APP) and microtuble associated protein tau
(MAPT) in those animals exposed to Pb [16, 17] . These mice were also shown
to have behavioral deficits at 18 and 24 months of age as measured by both the
water maze and Y-maze [18]. Recently, this same cohort was found to have
alterations of proteins involved in modifying epigenetic marks such as DNA
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methyltransferases, as well as significant changes in epigenetic marks
themselves; including significant decreases in total protein levels of H3K9Ac, an
important histone mark involved in gene activation [19] .
In this study, we have used a novel approach to examine H3K9Ac binding
across the genome. There are a limited number of papers that utilize Chromatin
Immunoprecipitation Sequencing (ChIP-seq) in brain tissue, as well as across
the lifespan. There are only a handful of studies that implement similar research
designs. A recent study reported genome wide alterations in histone acetylation
at sites H3K9 and H3K14 by using microarray analysis in a mouse model of
Huntington’s disease [20]. H4K12 was also examined using ChiP-seq
technology following learning and memory experiments in mice [21]. To the best
of our knowledge, this is the only study in which the active histone mark
(H3K9Ac) was analyzed across the lifespan as well as following an early life
developmental exposure.
In this manuscript we performed ChIP-seq analysis across the lifespan in
animals previously exposed to Pb compared to their age matched controls.
Tissue samples from three time points, PND 20, 270 and 700, were profiled for
H3K9Ac binding.
2. Methods
2.1 Animal Exposure:
C57BL/6 mice were bred in house in the Animal Care Facility at the
University of Rhode Island according to previously published protocols [19, 22,
23]. Postnatal day 1 (PND 1) was designated as 24 h after birth. Male pups from
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different dams were pooled and placed randomly to different dams
(10 mice/dam). The mice were divided into two groups, the control group
received regular tap water, and the second group (PbE, developmental
exposure) was exposed to 0.2% Pb acetate from PND 1 to PND 20 through the
drinking water of the dam. Cerebellar tissue from mice aged PND 20, 270, and
700 were used in this study. The animals used in this study have been
previously found to have Alzheimer’s pathology as well as behavioral deficits late
in life [16, 22, 23]. We have also shown alterations in epigenetic regulators as
well as epigenetic marks including histone proteins following exposure to Pb [19].
Specifically we observed significant decreases in levels of H3K9Ac across the
lifespan following exposure to Pb [19].
2.2 Tissue Fractionation and Shearing Optimization
Chromatin Isolation was performed using the reagents from the ChIP IT
Express Kit (Cat # 53008, 53032 Active Motif, Carlsbad CA) with modifications
for working with tissue samples. All solutions were prepared according to the
manufactures instructions. 100 mg of cerebellar tissue was pooled from mice
(n=5) and was homogenized in with 4 mL of phosphate buffer saline (PBS) (1 mL
per 25 mg of tissue), using dounce homogenizer. The cerebellum was used due
to its dense and abundant neuronal populations that would yield sufficient
material for these experiments. Samples were then incubated with 180 µl of 37%
formaldehyde and placed on a shaker at room temperature for 15 min, and
centrifuged at 3500 rpm for 8 min at 4°C. The supernatant was discarded, and
the pellet was resuspended with 10 mL of glycine stop fix solution and incubated
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at room temperature for 5 minutes on a shaker. The sample was then centrifuged
at 2500 rpm for 10 min at 4°C and pellet was washed with 1 mL ice cold PBS.
Samples were later centrifuged at 2500 rpm for 10 min at 4°C. The pellet was
resuspended with 1 mL ice-cold lysis buffer and incubated on ice for 40 min.
Samples were then centrifuged at 5000 rpm for 10 min at 4°C to pellet the nuclei.
The supernatant was discarded and 350 µl of ice-cold shearing buffer was added
to resuspend the nuclei.
Samples were sonicated using a Branson sonifier 150 on level 2. Each
sample was sonicated 4 times at 20 seconds with 40 second intervals while on
ice. The samples were centrifuged at 1500 rpm for 10 min at 4°C and
supernatant collected. A 50 µl aliquot of the supernatant was set aside for DNA
cleanup and concentration measurement, and the rest aliquoted for future ChIP
reactions. The DNA cleanup was performed by incubating the sample with 1 µl
RNase A at 37°C for 15 minutes, then with 10 µl Proteinase K at 42°C for 1.5 hr.
DNA was precipitated by phenol chloroform extraction 1:1 TE saturated pH 8
(Sigma, St Louis MO). The sample was centrifuged at maximum speed for 10
min at 4°C and the aqueous phase moved to a fresh tube. 20 µl of 3 M Sodium
Acetate pH 5.2 and 500 µl 100% ethanol was added to the sample followed by
overnight incubation at -80°C. The sample was then centrifuged for 15 minutes at
4°C, the pellet washed with 500 µl 70% ice cold ethanol, and resuspended with
30 µl double distilled ionized (DDI) water. Samples were quantified using a
nanodrop and run on a 2% agarose gel at 100V for 45 min. The gel was
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visualized using the Amersham Typhoon Imager Scanner FLA 9000 (GE Life
Sciences, Piscataway NJ) with the optimal fragment size between 200-500 bp.
2.3 Chromatin Immunopercipitation and Validation
ChIP Reactions were set up in 100 µl volumes as described in the ChIP IT
Express Kit (Active Motif) with minor modifications. The antibody concentration
for H3K9Ac (Cat #39137 Active Motif) was used at a concentration of 5 µg
instead of the recommended 1-3 µg. Sheared chromatin was used at a
concentration of 30 µg. The samples were incubated overnight on a rotating
platform, at 4°C. The rest of the protocol was followed without modification.
DNA purification was performed using the Agencourt® Ampure XP DNA
Purification beads (Cat #A63880 Beckman Coulter, Brea CA). Samples were
fully resuspended with 200 µl of Ampure XP beads, and incubated for 10 min at
room temperature. Using a magnetic stand the samples were washed with 200 µl
of 70% ethanol. Beads were allowed to air dry on the magnet, and DNA eluted
using nuclease free water. DNA was quantified using Nanodrop UV/VIS
Spectrophotometer (Thermo Scientific, Wilmington DE). To ensure successful
chromatin, pull downs were performed. RT-PCR was performed using
commercially available positive and negative control primers. A positive primer
for the promoter region of GAPDH was utilized (Cat # 71018 Active Motif), the
negative control primers used were for a gene desert on chromosome 6 (Cat #
71011, Active Motif) and gene desert on chromosome 17 (Cat # 71012, Active
Motif). RT-PCR was performed in 20 µl reaction volumes, utilizing 10 ng of DNA,
10ul SYBR green PCR master mix (Applied Biosystems, Foster City, CA) and 4
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ul of the active motif primer. RT-PCR was performed using the ViiA7 Real-Time
PCR System (Applied Biosystems) under the following conditions: 50°C for 2 min
followed by 95°C for 10 min, then 40 cycles of 95°C for 15 sec and 60°C for 1
min. Normalization of the data was performed using the ChIPed DNA of each
sample against the inputs for each sample for both the positive and negative
control primers using the 2-ΔΔCT method.
2.4 Library Preparation, Quality Check and Run Conditions
The next generation sequencing (NGS) library was prepared using the
Ovation Ultralow System VS2 1-16 (Cat# 0344 Nugen San Carlos, CA). The
samples were prepared at the Brown University Sequencing Facility, according to
the manufactures protocols. Briefly, 25 ng of ChIPed DNA was end repaired, and
adapters were added to each sample and ligated to distinguish samples from
each other on the flow cell. Following ligation, the samples were purified and
amplified by 10 cycles of PCR. Samples were quantified using the Qubit dsDNA
BR Assay Kit (Cat # Q32850 Life Technologies, Carlsbad CA).
Fragment analysis was performed using the High Sensitivity NGS
Fragment Analysis Kit (Cat# DNF-474 Advanced Analytical Technologies,
Ankeny IA) using 2 µl of library input at a concentration of 4-6 ng/µl following the
manufactures instructions. For each library 1:1000, 1:5000, and 1:1000 dilutions
were made using the Kapa Library Quantification Kit (Cat #KK4873 Illumina San
Diego, CA), each dilution was run in triplicate on ViiA7 Real-Time PCR System
(Applied Biosystems). Reaction volume of 20 µl were run under the following
conditions: 95°C for 5 min, then 35 cycles of 95°C for 20 sec, 60°C for 45 sec.
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Samples were excluded from analysis if the standard deviation from the median
was >0.1 Ct units. The total amount of library was determined for each library
dilution using six know amplification standards with an amplification product size
of 462 bp. The median concentration of the library was calculated using all three
dilutions.
Samples were pooled and submitted for sequencing at 20 nM
concentration to the Bauer Sequencing Facility at Harvard University. The
samples were processed using the Illumina Hiseq 2500 system in rapid run mode
producing 1 X 50 bp single reads. One sample was run on two lanes of a whole
flow cell according to standard protocol performed at the Bauer center.
2.5 Bioinformatics Analysis
The raw data from ChiP-seq was analyzed in-house at the University of
Rhode Island by the Biomedical Research Bioinformatics Core. Each tagged
sample was end to end aligned to the mouse genome using Bowtie2 allowing for
one mismatch between sequences [24, 25]. Files were then converted to bed
files using SAMtools [26]. To determine H3K9Ac sites, peak calling was
performed using SICER peak sites in the Pb group, as well as the control group.
The Pb data set was then filtered against the control data set for each timepoint,
leaving only peaks unique to the Pb exposed animal. The analysis was
performed using a false discovery rate (FDR) of 0.01, and parameters specified
from previously published protocols [27]. Peak annotation was later performed
using the homer program with gene ontology and genome ontology [28].
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3. Results
3.I H3K9Ac Promoter Analysis
The homer peak annotation output provided H3K9Ac peaks for all
genomic regions including promoters, exons, introns and intergenic regions. For
the purpose of this manuscript, these data were filtered out and the results
reported here are only for promoter regions, defined by homer as -1000 to +1000
bp from the transcription start site (TSS). All comparisons were made using the
filtered peak program from SICER, which subtracted control animal peaks at
each timepoint from the Pb exposed animal peaks.
In all three data sets, peaks were sorted to corresponding genes to
identify how many genes had increased H3K9Ac peaks in the promoter region.
We identified 405 genes at day 20, 62 genes at day 270 and 7220 genes at day
700 with H3K9Ac binding peaks after subtracting the control group peaks from
each data set (Figure 1). We then identified which genes were common between
day 20 animals and day 700, as well as day 270 and day 700. For the day 20
samples, 293 genes had an increase in H3K9Ac peaks in their promoter,
whereas only 112 genes were shared with the day 700. Similarly at day 270, 48
genes were unique, whereas 14 genes were shared with the day 700 group
(Figure 2).
Data files were then run by Homer and analyzed against the Kyoto
Encyclopedia of Genes and Genomes (KEGG). The KEGG pathway database
has a specific pathway of genes implicated in AD (ko5010)[29, 30]. At the
promoter level, Apbb1 was the only gene to have an increase in H3K9Ac peaks
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at the promoter in day 20 mice. There were no genes found to have increased
acetylation at the day 270 time-point. However, at day 700, 74 genes implicated
in Alzheimer’s were found to have increased H3K9Ac in the promoter region
(Figure 3). A complete list of these genes can be found in Table 1.
For promoter regions, visualization of H3K9Ac islands are demonstrated in
Figure 4. The degree of abundance is presented in the top trace in the UCSC
browser[31]. The higher degree of shading indicates the higher abundance of
reads to that specific sequence in the genome. Three genes of interest to
Alzheimer’s pathology are presented, Apoe, App and Mapt. In all three of the
traces, there is a high degree of H3K9Ac binding in the region immediately
before the first exon, and within the first exon and first intron (Figure 4). The
acetylation peaks for a subset of the 74 genes were calculated (Figure 5). These
gens were chosen based on their association with App and Mapt.
3.2 Genome Wide KEGG Analysis
This analysis utilized the entire genomic data set including all previously
excluded elements (exons, introns, intergenic regions) to determine statistical
significance. Using this technique, the filtered data identified a statistically
significant increase in H3K9Ac peaks in the Alzheimer’s pathway. At day 20, 29
genes were identified (P=0.0225) and at day 700, 96 genes were identified
(P=.000103). A full list of these genes can be found in Table 2.
4. Discussion
ChiP sequencing is a powerful tool used to identify binding sites of
transcription factors or histone marks to DNA regions. It is also the preferred
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method when working with larger genomes such as the human or mouse
genome[32]. The design and sequence run of this experiment was specifically
chosen based on the number of reads required to detect significant changes in
histone marks in the genome. The Encyclopedia of DNA Elements (ENCODE)
consortia has identified the appropriate number of reads for mapping histone
marks at a threshold greater than 10 million reads per sample [33]. This
experiment yielded between 17-19 million reads per sample for H3K9Ac, a mark
well known for its role in activating gene expression. Due to the abundance of
genome reads, the analysis and figures were created to examine genes with
increased acetylation sites in the promoter regions, rather than all genomic
regions. Furthermore, a study by Roh et al., determined that H3K9Ac islands
present in the promoter, as well as the 5’UTR, appear to be more involved in
regulating gene expression than those acetylation sites present in all other
regions of the genome [34].
These data indicate that there is an abundance of acetylation sites in a
number of genes in animals developmentally exposed to Pb. Specifically, when
we subtract the H3K9Ac peaks of the control animals at each time point from the
Pb peaks we identified 7220 genes with distinct peaks at day 700, these effects
were much smaller in the day 20, and day 270 timepoints (Figure 1). From our
data, wee see there are considereably less peaks in the day 270 timepoint, which
would suggest that consequences of developmental exposure to Pb manifest
themselves at the end of life. Based on these data we would expect there to be
an upregulation at the majority of the genes at day 700, due the role H3K9Ac in
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regulating gene expression. For genes previously examined such as those
involved in AD, this fits our previous findings [18, 23, 35]. However, these results
will be validated in future studies examining genes in other pathways.
The KEGG genomic database links genes and genetic information to
higher order functional categories, such as molecular function and disease
pathology [29]. Specifically, the ko0510 pathway identified 162 genes that have
been associated with AD pathology. These genes are involved in App
processing, Tau phosphorylation, as well as mitochondrial and calcium
dyfunction and endoplasmic reticulum stress. At day 700, 74 of these genes have
an increase in acetylation peaks in their promoter regions (Table 1 and Figure 3).
This increase in H3K9Ac peaks in the promoter indicates there is a high
likelihood that these genes would in turn be upregulated following exposure to
Pb. When we examined the entire genome using the KEGG database, we found
statistically significant changes in a number of genes at both the day 20
timepoint, as well as the day 700 timepoint (Table 2). Although not the promoter
region, these H3K9Ac could also be playing a role in regulating gene expression
and will require further analysis.
Other studies have implicated histone acetylation involvement in memory
impairment, as well as in specific gene loci related to AD [10, 36]. In vitro
treatment with thyroid hormone lead to a decrease in H3K9Ac binding in the
promoter of APP, and subsequently a decrease in expression, these effects were
reduced with subsequent treatment with histone deacetylase inhibitors
(HDAC)[37]. Similarly, in animal models of AD treatments with HDAC inhibitors
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have been explored as potential therapeutics and have been shown to improve
learning and memory deficits in animals [38]. While studies have reported
hypoacetylation at genes related to memory and learning, others similar to our
own have identified hyperacetylation of genes involved in the pathology [39]. The
relationship between histone acetylation and AD is complex, and likely involves
both cases of hypo as well as hyperacetylation of genes, as recently reviewed
[36].
These data will be further analyzed using bioinformatics methods utilizing
the entire genome, as well as specified promoter inputs. Although we focused
our analysis on the promoter region in this manuscript due to the importance of
acetylation sites in this region, there are known regulation sites throughout the
genome further than 1000 bp from the TSS [40]. These enhancer elements have
been shown by others to also interact with histone proteins to influence gene
expression [40]. We will also analyze samples across time, independent of
normalization to the control animals to identify ways in which Pb exposed mice
differ from one another across their lifespan in acetylation peaks, the same
analysis will be performed in the control group to analyze the effects of aging.
Although these findings are preliminary, they are novel in that we have
identified a potential epigenetic mechanism by which these AD genes become
upregulated in a model that we have worked with for over a decade. We have
provided evidence for H3K9Ac as a potential regulator in a number of AD related
gene promoters. This increase in H3K9Ac may contribute, or may be driving the
increase in gene expression that we have seen in previous publications.
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Figure 1. Acetylation Peaks in Promoter Regions. The total number of genes
by time point (Blue); day 700 (red); day 270 and (green); day 20 Pb exposed
animals normalized to their control counterparts with acetylated peaks in their
promoter.

83

Figure 2. Common Genes with Acetylation Peaks in the Promoter Region.
The total number of unique genes with acetylation peaks are shown for each time
point in Pb exposed animals normalized to their control counterparts. The
common number of genes shared between both time points is represented
between them.
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Figure 3. Acetylation Peaks in Promoters of Genes in the ko5010 Pathway.
Of the 162 genes in the Alzheimer’s k05010 pathway, 74 of them have genes
with acetylated sites in their promoter in the Pb exposed animals at day 700
relative to their control counterparts.
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Figure 4. Acetylation Island Regions of AD related genes. The island filtered
trace was created by filtering all of the control peaks from the Pb peaks at Day
700. This was then visualized using the UCSC genome web browser. The
shading represents relative abundance of reads at that particular site or location,
with the darkest shading indicating the most abundant reads in that region. The
following genes are represented, A) Apoe, B) App, and C) Mapt, all indicating an
enrichment of H3K9Ac either at or near their promoter regions.
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Figure 5. Promoter Acetylation of Genes involved in APP and Tau
Pathology. Total number of acetylation sites were counted in the promoter
region of genes involved in both APP and TAU pathology.
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I. Pb day 700 normalized to Control day 700
Target genes: 74
Tau regulation: Cdk5, Mapt, Gsk3b, Cdk5r1
APP processing: Apoe, Psen2, Apbb1, Lrp1, Psenen, App, Bace1
Mitochondrial, endoplasmic reticulum dysfunction and Ca2+ signaling:
Ndufa3, Ppp3cb, Ndufa8, Eif2ak3, Ndufc1, Ndufb7, Ppp3cc, Atp5g2, Sdhb, Plcb1,
Adam10, Capn2, Apaf1, Atp5j, Itpr3, Atp5a1, Ndufa13, Ppp3ca, Ndufa4, Calm1,
Cox5a, Gnaq, Cox5b, Ndufab1, Ndufb4, Cox6a1, Cycs, Ndufa6, Ern1, Grin2a,
Grin2d, Calm2, Ndufa5, Gapdh, Casp9, Aph1a, Ppp3r1, Grin2c, Bad, Atp5f1, Calm3,
Cox4i1, Aph1c, Ndufb2, Atp5d, Ndufa7, Ndufs1, Grin1, Cacna1c, Uqcrq, Capn1, Itpr2,
Atp5g3, Ndufv1, Casp7, Atp5b, Mapk1, Ndufb6, Atp5h, Ncstn, Cyc1, Atp2a2, Uqcrfs1
Table 1. Presence of acetylation islands in promoters of genes associated
with AD . The gene database used for analysis was the ko5010. Genes with
acetylation islands in the Pb exposed group at day 700, which were absent in the
day 700 control group.

88

A. Pb day 20 normalized to Control day 20
Target genes: 29

P value: 0.022533815

Tau regulation: Mapt, Cdk5r1
APP processing: Apbb1, Psen2, Lrp1, Ide
Mitochondrial, endoplasmic reticulum dysfunction and Ca2+ signaling: Cacna1c,
Capn1, Atp2a3, Atp5o, Ndufs7, Ndufs8, Ndufb7, Uqcr10, Cox7a1, Uqcr11, Capn2,
Cacna1d, Ndufb9, Nos1, Grin2d, Calm2, Cox7a2l, Cacna1s, Atp2a2, Cox8b, Ndufa4l2,
Grin2c, Ndufa13

B. Pb day 700 normalized to Control day 700
Target genes: 96

P value: 0.000103327

Tau regulation: Mapt, Cdk5, Cdk5r1, Gsk3b
APP processing: Apoe, Psen2, Bace2, Psenen, Bace1, App, Lrp1, Apbb1
Mitochondrial, endoplasmic reticulum dysfunction and Ca2+ signaling:
Ndufa3, Ndufs7, Ppp3cb, Ndufa8, Eif2ak3, Ndufc1, Ndufb7, Ppp3cc, Atp5g2, Sdhb,
Plcb1, Adam10, Cacna1d, Capn2, Cox8c, Apaf1, Atp5j, Itpr3, Atp5a1, Ndufa4l2,
Ndufa13, Ppp3ca, Ndufa4, Calm1, Cox5a, Ryr3, Cox6a1, Cycs, Ndufa6, Ern1, Grin2a,
Nos1, Grin2d, Calm2, Ide, Ndufa5, , Uqcrfs1, Cox7c, Atf6, Ppp3r1, Grin2c, Cox6b2,
Bad, Atp5f1, Calm3, Cox4i1, Aph1c, Ndufb2, Atp5d, Uqcrb, Calm5, Ndufa7, Grin2b,
Ndufs1, Grin1, Gnaq, Cox5b, Ndufab1, Plcb3, Ndufb4, Atp5o, Cacna1c, Uqcrq,
Ndufa12, Capn1, Itpr2, Atp5g3, Ndufv1, Casp7, Atp5b, Mapk1, Ndufb6, Atp5h, Ncstn,
Cacna1s, Ndufs4, Cyc1, Plcb4, Atp2a2, Casp8, Gapdh, Casp9, Aph1a, Mapk3

Table 2. Presence of acetylation islands in genes associated in AD as
defined by the KEGG ko5010 database. (A) List of genes with statistically
significant (p <0.05) acetylation islands in the Pb exposed group at day 20, which
were absent in the control day 20. (B). List of genes with statistically significant
(p<0.001) acetylation islands in the Pb exposed group at day 700, which were
absent in the day 700 control.
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Appendix 1
A Mechanistic Proposal for The Actions of Lead on the Aging Brain
In our model of developmental lead (Pb) exposure, male C57BL6J pups
are exposed to 0.2% Pb acetate through the drinking water of the dam, and the
control group receives regular tap water from postnatal day (PND) 1-20. Previous
publications by us have shown that this level of Pb results in a concentration in
the cerebellum of PND 20 rodents (0.25 +/- 0.07 µg/g [1], and blood lead level
has been shown to be 46.43 µg/dl during Pb exposure, both measurements are
undetectable in adults [2]. As amply cited in the manuscripts of this dissertation,
we have published that this developmental exposure is accompanied by a
transient increase during development and a latent increase in Alzheimer’s
disease (AD) related biomarkers in old age [3-5]. We have also previously
reported that exposure to Pb during early life results in global hypermethylation
patterns as well as global downregulation of many genes [6, 7]. However, a small
subset of genes exhibit either hypomethylation or are up-regulated by pathways
independent of DNA methylation; AD-related genes are among them.
In manuscript III, we have reported a number of genes involved in AD with
increased acetylation peaks in their promoter region. Histone acetylation at gene
promoters is indicative of increased gene expression, and would support our
model and previous findings. From these new data uncovered by our ChIP-seq
study with histone acetylation, we hypothesize the following mechanisms of
action by which Pb may be acting to modify gene expression.
Our ChiP-seq data indicates that a number of histone deacetylase (HDAC)
genes lack histone acetylation peaks in their promoters, both in early and late in
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life. Therefore we would expect the expression of these genes to be downregulated. This may be occurring by DNA methylation patterns that are more
stable and persist over time, especially in neurons where we have little to no
turnover in cells. Therefore, our Pb exposure may be enhancing DNA
methylation at these gene promoters. HDAC proteins function primarily to
deacetylate histones, if we are repressing these proteins we could then in turn be
enhancing histone acetylation throughout the lifespan, which is what is observed
in our data set.
We also believe that HDAC proteins may be directly targeted during the
exposure period in early life due to the fact that HDAC proteins have a zinc
finger-binding domain. Early work by the Zawia lab in the 1990s has shown that
Pb can interact and disrupt zinc finger proteins, making HDAC proteins a prime
target. This maybe one mechanism by which Pb is modifying gene expression
early in life, it may also partially explain our global reprogramming of genes both
by histone proteins as well as DNA methylation.
The changes observed in our animal model are greatly exacerbated in the
aging brain, and we believe this is due to an increase in a number of different
pathways such as, an increase in reactive oxygen species, increased
inflammatory responses, and mitochondrial dysfunction. We believe that early life
reprogramming of gene expression due to environmental exposure undermine
our ability to combat insults that occurring during aging.
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